DNA Today: A Genetics Podcast okładka

DNA Today: A Genetics Podcast

DNA Today: A Genetics Podcast

Autor: Kira Dineen Gene Pool Media
Słuchaj bezpłatnie, bez subskrypcji

Das größte Angebot der Saison | 0,99 € pro Monat für die ersten 3 Monate + 15 € Audible-Guthaben

Danach 6,99 €/Monat. Bedingungen gelten. Monatlich kündbar.
O tym tytule

Discover New Advances in the world of genetics, from technology like CRISPR to rare diseases to new research. For 14 years, multi-award winning podcast ”DNA Today” has brought you the voices of leaders in genetics. Host Kira Dineen brings her genetics expertise to interview geneticists, genetic counselors, patient advocates, biotech leaders, researchers, and more.

***Best Science and Medicine Podcast Award Winner (2020, 2021 and 2022)***

Learn more (and stream all 400+ episodes) at DNAtoday.com. You can contact the show at info@DNAtoday.com.


This show is part of "Gene Pool Media: The Science Podcast Network" head to GenePoolMedia.com to explore all our science themed shows.

DNA Today, LLC 2012-2026
Nauka
  • #420 NSGC 2026: Ambry's Whole Genome Sequencing and BillionToOne's Unity Confirm
    Nov 14 2026
    In this episode, we're coming to you from Baltimore for the National Society of Genetic Counselors (NSGC) 2026 Annual Conference! From new approaches to whole genome sequencing to the ability to analyze intact fetal cells through a pregnant person’s blood sample, we're exploring two exciting advances in genetic testing that could change how patients receive answers. Host Kira Dineen sits down with experts from Ambry Genetics and BillionToOne to discuss new technologies unveiled at the conference, their clinical applications, and how they could improve diagnostic accuracy and accessibility. We also celebrate Genetic Counselor Appreciation Day, highlight memorable moments from NSGC 2026, and share a special thank-you following Kira's recognition with the NSGC Leader in Community Engagement Award! Featured Guests Thomas "TJ" Slavin Jr., MD, is the Chief Medical Officer of Ambry Genetics and a medical geneticist. He joins us to discuss Ambry Genetics' newly launched whole genome sequencing offerings, GenomeNext and GenomeReveal, and how integrating RNA analysis, pangenome references, and proactive reanalysis could help end the diagnostic odyssey for more families. Jennifer "Jen" Hoskovec, MS, CGC, is Vice President of Medical Affairs at BillionToOne and a past president of NSGC (2014). She returns to DNA Today to introduce Unity Confirm, a new prenatal testing option that isolates and sequences intact circulating placental cells from a pregnant person’s blood to provide additional information following high-risk NIPT results. In This Episode We Discuss Ambry Genetics: Whole Genome Sequencing, RNA Analysis, and the Pangenome How Tempus' acquisition of Ambry Genetics brings together tumor sequencing and germline testing capabilities.Why Ambry chose 2026 to launch GenomeNext and GenomeReveal and how whole genome sequencing is changing rare disease diagnostics.How RNA analysis can help clarify variants of uncertain significance (VUS), particularly variants that may affect RNA splicing.Why incorporating a human pangenome reference can improve variant detection across diverse ancestral populations and help address disparities in genetic testing.How Ambry's Patient for Life program proactively reanalyzes genetic data and contacts providers when new evidence leads to clinically meaningful changes.Why identifying dual genetic diagnoses is increasingly important and how ongoing reanalysis can reveal additional explanations for a patient's symptoms. BillionToOne: Unity Confirm and Cell-Based Prenatal Testing How Unity Confirm differs from traditional cell-free DNA screening by isolating intact circulating extravillous trophoblasts from a pregnant person’s blood.How sequencing individual placental cells can provide additional information following a high-risk NIPT result.Why Unity Confirm is positioned as an additional testing option rather than a replacement for diagnostic procedures such as chorionic villus sampling (CVS) or amniocentesis.How this technology could help patients who decline invasive testing or face geographic, financial, or gestational-age barriers to accessing diagnostic procedures.The limitations of analyzing a small number of cells, particularly when considering placental mosaicism and conditions such as Turner syndrome.How staining techniques and genetic comparisons help distinguish placental trophoblasts from maternal white blood cells.How genetic counselors can integrate another source of prenatal information into patient-centered conversations about screening, diagnosis, and reproductive decision-making. Resources & Links NSGC Annual Conference National Society of Genetic Counselors (NSGC) – Learn more about NSGC, its annual conference, and resources for genetic counseling professionals. Ambry Genetics and Whole Genome Sequencing Ambry Genetics – Explore Ambry's clinical genetic testing services and resources. GenomeNext and GenomeReveal Launch Announcement – Learn how Ambry integrates whole genome sequencing, RNA analysis, pangenome references, and ongoing reanalysis to improve rare disease diagnosis. GenomeNext and GenomeReveal – Explore the technologies and clinical capabilities behind Ambry's new whole genome sequencing offerings. Patient for Life White Paper – Learn how Ambry's proactive reanalysis program identifies new diagnostic findings as genetic knowledge evolves. Tempus AI – Learn about Ambry's parent company and its work in precision medicine. Fact Check: Kira misspoke when she said Ambry has been analyzing RNA as part of clinical testing for 15 years, she was thinking of Ambry offering the first clinical exome as that was launched in 2011. BillionToOne and Prenatal Testing BillionToOne – Explore the company's prenatal genetic testing technologies. Unity Confirm White Paper: Initial Clinical Outcomes of a Circulating Fetal Cell Assay – Review the initial clinical findings and learn how circulating placental cells are isolated, identified, and ...
    Rozwiń Zwiń
    31 min
  • #419 Optical Genome Mapping and Long-Read Sequencing: Unlocking Rare Diagnoses
    Nov 6 2026
    What happens when traditional genetic testing leaves patients and families without answers? Emerging technologies like optical genome mapping (OGM) and long-read sequencing are expanding what laboratories can detect, from complex structural variants to difficult-to-analyze repetitive regions of the genome. These advances are already changing clinical testing strategies and helping uncover diagnoses that previously remained out of reach. In this episode, we welcome back Dr. Nikhil Sahajpal, Assistant Laboratory Director at Greenwood Genetic Center (GGC), who previously joined us in Episode 362 to introduce optical genome mapping. Now, nearly two years after GGC began offering OGM clinically, Dr. Sahajpal shares how the technology is being integrated into rare disease diagnostics, including additional diagnostic findings in at least 5% of previously unsolved cases. The conversation takes a closer look at facioscapulohumeral muscular dystrophy (FSHD), a genetically complex condition involving D4Z4 repeat contractions, epigenetic changes, and inappropriate DUX4 expression. Dr. Sahajpal explains how OGM and short-read sequencing can work together to distinguish FSHD1 from FSHD2, and why the laboratory is evaluating long-read sequencing as a potential way to streamline this testing. We also explore targeted applications of OGM and long-read sequencing, including clarifying DMD duplications, mapping structural variant breakpoints, and determining whether variants are in cis or trans. Finally, Dr. Sahajpal discusses where long-read genome sequencing fits into the rare disease diagnostic workflow and whether a more comprehensive, unified genetic test could eventually reduce the need for multiple testing platforms. Episode Discussion Topics How optical genome mapping compares with karyotyping, FISH, and chromosomal microarrayGreenwood Genetic Center's clinical experience with OGM and its additional diagnostic yield in previously unsolved rare disease casesWhen OGM may serve as a reflex test following negative genome sequencingThe genetics of FSHD1, including D4Z4 repeat contractions, permissive haplotypes, and DUX4 expressionWhy chromosome 4 and chromosome 10 repeat regions complicate FSHD testingHow OGM and short-read sequencing contribute to distinguishing FSHD1 and FSHD2The potential for long-read sequencing to assess repeat size, sequence variants, and DNA methylationWhen long-read genome sequencing may be appropriate for patients with broad or nonspecific phenotypesHow targeted OGM can clarify DMD duplications and change carrier screening interpretationUsing targeted long-read sequencing to phase variants in recessive conditions without parental samplesThe limitations of phenotype-driven variant analysis and the future of comprehensive genomic testing Resources & Links Greenwood Genetic Center OGM CompleteOGM Targeted Facioscapulohumeral Muscular Dystrophy Type 2 (FSHD2) NGS PanelFSHD1Long-read Sequencing-Trio Analysis Long-read Sequencing-Targeted Analysis Sahajpal Completes Laboratory Fellowship at GGC and Joins FacultySahajpal NS, Mondal AK, Singh H, Vashisht A, Ananth S, Saul D, Hastie AR, Hilton B, DuPont BR, Savage NM, Kota V, Chaubey A, Cortes JE, Kolhe R. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers. Cancers (Basel). 2023 Jun 16;15(12):3214. doi: 10.3390/cancers15123214. PMID: 37370824; PMCID: PMC10296552. Relevant DNA Today Podcast Episode #362 Optical Genome Mapping: Detecting Structural Variants Missed by Traditional Tests (with guest Dr. Nikhil Sahajpal)#279 Reflecting on 50 Years of Greenwood Genetic Center#183 Dr. Miga and Dr. Phillippy on the Telomere to Telomere Consortium#182 Eric Green on the Complete Human Genome Project #145 Greenwood Genetic Center on Epigenetics Connect with DNA Today: You never have to wait long for a new episode of DNA Today, we release episodes every Friday! In the meantime, explore our library of over 400 episodes on Apple Podcasts, Spotify, DNAToday.com, or wherever you listen to podcasts. Just search “DNA Today.” Prefer to watch? The video version of this episode is available on our YouTube channel and DNAToday.com. Select episodes are filmed in person, including some at the iconic NBCUniversal studios. Discover more podcasts exploring genetics, genomics, medicine, and science from our network, Gene Pool Media: The Science Podcast Network. DNA Today is hosted and executive produced by Kira Dineen, MS, LCGC, CG(ASCP)CM. Liv Davidson is our Social Media Lead and Eric Knaus is our Digital Marketing and Automation Lead. Follow us at @DNATodayPodcast on all platforms including Instagram, X, BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. Questions, partnership inquiries, and guest pitches can be sent to info@DNAToday.com.
    Rozwiń Zwiń
    39 min
  • #418 Hypophosphatasia Genetics: One Gene, Many Presentations
    Oct 30 2026
    How can variants in the same gene cause life-threatening disease in infancy for some individuals, while others experience mild symptoms or remain asymptomatic? Hypophosphatasia (HPP) challenges traditional expectations about genetic inheritance, with both autosomal dominant and autosomal recessive forms and a remarkably broad spectrum of clinical presentations. In this episode, recorded in person in Nashville, our guest is Dr. Kathryn Dahir, Professor of Medicine in the Division of Diabetes, Endocrinology, and Metabolism at Vanderbilt University Medical Center and Director of the Program for Metabolic Bone Disorders. Drawing on decades of experience caring for patients with rare skeletal conditions, Dr. Dahir explores the complex genetics of HPP and why understanding a patient's clinical presentation is just as important as interpreting their genetic test results. The conversation begins with a patient case that challenged Dr. Dahir's understanding of HPP. Initially treated for osteoporosis, the patient experienced recurrent fractures and worsening symptoms despite treatment. Further investigation revealed impaired bone mineralization, low alkaline phosphatase (ALP), and a single ALPL variant, illustrating how individuals with one affected copy of the gene can experience significant disease. Dr. Dahir explains how the ALPL gene encodes tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme essential for healthy bone mineralization, and how disruption of its activity contributes to the manifestations of HPP. We explore the differences between autosomal dominant and autosomal recessive inheritance, the challenges of predicting disease severity from genetic testing alone, and why even relatives carrying the same ALPL variant may have very different symptoms. Dr. Dahir discusses the importance of identifying variants in cis or trans, recognizing deletions and duplications, evaluating variants of uncertain significance, and considering how genetic modifiers, environmental exposures, and coexisting conditions can influence a patient's presentation. Finally, we discuss the evolving landscape of HPP genetic testing, including the importance of longitudinal follow-up, resources such as the global ALPL variant database, and ongoing efforts to improve variant classification. As genomic testing becomes increasingly accessible, this conversation highlights both its potential to improve rare disease diagnosis and the limitations of using genetics alone to predict an individual's future health. Episode Discussion Topics Dr. Dahir's clinical experience treating HPP and other rare metabolic bone disorders at Vanderbilt University Medical CenterWhy genetic testing must be interpreted alongside clinical symptoms, biochemical findings, and patient historyA patient case illustrating how HPP can be mistaken for osteoporosis and why low alkaline phosphatase is an important diagnostic clueHow the ALPL gene and tissue-nonspecific alkaline phosphatase (TNSALP) regulate bone mineralizationThe differences between autosomal dominant and autosomal recessive HPP and the challenges of distinguishing affected individuals from asymptomatic carriersWhy genotype-phenotype correlations in HPP are complex, even among family members with the same genetic variantThe importance of determining whether variants are in cis or trans and identifying deletions or duplications that some testing platforms may missHow modifier genes, epigenetics, medication exposures, and coexisting medical conditions may influence HPP symptoms and severityInterpreting variants of uncertain significance and the importance of genetic counseling, variant reclassification, and long-term follow-upThe role of the global ALPL variant database in improving classification and understanding the clinical significance of genetic variantsFuture opportunities to identify protective genetic factors and improve predictions of disease progression About the HPP Series This episode is the first in a three-part educational series about hypophosphatasia. Stay tuned for the next installment . Across the series, we explore the clinical spectrum and diagnosis of HPP, its genetic basis and variable expression, and considerations for genetic counseling and management. This series is sponsored by Alexion. The views expressed by the host and guests are their own. Resources & Links Vanderbilt University Medical CenterAlexion, AstraZeneca Rare Disease ALPL Gene Variant DatabaseSoft Bones: The U.S. Hypophosphatasia Foundation provides education, support, advocacy, and community resources for individuals and families affected by HPP.Explore Soft Bones’ HPP resources, including educational materials for patients, caregivers, and healthcare professionals. Publications Dahir KM, Below JE, Liu J, Javid A, Wang G, Bastarache L. Hypophosphatasia: low penetrance of pathogenic and likely-pathogenic ALPL variants identified through an unselected biorepository. J Bone Miner Res. 2026 Mar 2;41(3):...
    Rozwiń Zwiń
    35 min
adbl_web_anon_alc_button_suppression_t1
Brak recenzji